# EDGAR Filing Document

**Accession Number:** 0001847846
**File Stem:** 0001493152-26-019415
**Filing Date:** 2026-4
**Character Count:** 9749
**Document Hash:** f0a92153ddccd802435d412f07af247d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-019415.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001493152-26-019415

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260428

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EUDA Health Holdings Ltd
- **CENTRAL INDEX KEY:** 0001847846
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40678
- **FILM NUMBER:** 26909473

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 60 KAKI BUKIT PLACE, #03-01
- **CITY:** EUNOS TECHPARK
- **PROVINCE COUNTRY:** U0
- **ZIP:** 415979
- **BUSINESS PHONE:** 65 67880388

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 60 KAKI BUKIT PLACE, #03-01
- **CITY:** EUNOS TECHPARK
- **PROVINCE COUNTRY:** U0
- **ZIP:** 415979

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 8i Acquisition 2 Corp.
- **DATE OF NAME CHANGE:** 20210224

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of April 2026**

**Commission File Number: 001-40678**

**EUDA Health Holdings Limited**

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: +65 6327 1110

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

**Other Events.**

On April 28, 2026 EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.

**Exhibits**

99.1 [Press release dated April 28, 2026](ex99-1.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | |
|:---|:---|
| Dated: April 28, 2026 | Dated: April 28, 2026 |
| **EUDA Health Holdings Limited** | **EUDA Health Holdings Limited** |
| By: | */s/ Alfred Lim* |
|  | Alfred Lim |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development**

**SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) —** EUDA Health Holdings Limited (NASDAQ: EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen Inno Immune Co., Ltd. ("Shenzhen Inno"), a developer of cellular therapies in China, has received official approval under the 2025 Shenzhen Key Industry R&D Program.

The Shenzhen Key Industry R&D Program is a government-run initiative designed to support critical technological innovation and industrial development. The approved project is scheduled to be implemented from January 1, 2026, to December 31, 2028, under the supervision of the Shenzhen Science and Technology Innovation Bureau (the "Bureau"). Following this approval, it is expected that the Bureau may provide funding of up to approximately US$434,688 to support Shenzhen Inno's "Key Technology Development of TCR-T Therapy for Solid Tumors" project.

Pursuant to a non-exclusive distribution arrangement, EUDA holds the rights to market and sell selected immunotherapies provided by Shenzhen Inno to customers in Malaysia through its subsidiary CK Health Plus Sdn Bhd, with treatments conducted in China.

**Shenzhen Inno's Project Highlights & Scientific Focus**

Shenzhen Inno's project focuses on the development of TCR-T cell therapies targeting solid tumors, an area of oncology that remains challenging due to tumor heterogeneity and immune resistance.

● **Broad Target Coverage**

Development of HLA-restricted epitopes targeting cancer-testis antigens with high expression across multiple tumor types, with an initial focus on epitopes prevalent within the Chinese population.

● **AI-Driven Antigen Screening Platform**

Utilization of high-throughput, AI-driven screening technologies to identify optimized TCR candidates, in collaboration with leading research institutions including Shenzhen Bay Laboratory and the Shenzhen Institutes of Advanced Technology under the Chinese Academy of Sciences.

● **Enhanced Cellular Engineering**

Engineering of TCR-T cells designed to address key therapeutic limitations such as T-cell exhaustion and limited persistence within the tumor microenvironment, with the objective of improving durability and efficacy.

● **Integrated Research and Clinical Framework**

Collaboration with Shenzhen People's Hospital to conduct exploratory clinical studies evaluating safety and efficacy, alongside the development of standardized yet adaptable manufacturing processes for advanced cellular therapies.

**Strategic Relevance to EUDA**

The approval of this project under a government-led program reflects continued progress in cellular immunotherapy development and aligns with EUDA's strategy to expand access to advanced treatment modalities through its commercial channels. This development provides EUDA with continued exposure to next-generation T-cell therapies within its existing distribution scope. Through its distribution framework, EUDA facilitates the delivery of science-driven healthcare solutions to its customers while maintaining a commercially focused approach to advanced therapies.

**Mr. Alfred Lim, Chief Executive Officer of EUDA, commented:**

"The approval of this project reflects ongoing progress in advanced cellular therapy research. Developments in areas such as TCR-T therapy continue to expand the scope of future treatment possibilities, and EUDA remains focused on identifying opportunities to bring clinically relevant innovations to our customers."

**About EUDA Health Holdings Limited**

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

**Forward-Looking Statements**

Certain statements in this press release that are not historical facts constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that refer to expectations or other characterizations of future events, circumstances or results are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The factors may include, but not be limited to, factors related to the Company's anticipated growth strategies, future business development, ability to develop new products, expand to other related industries or markets, and other information detailed from time to time in the filings and future filings with the United States Securities and Exchange Commission. The views expressed are those of management and are based on currently available information. Estimates and projections contained herein have been prepared by management and involve significant elements of subjective judgment and analysis and are based on certain assumptions. No representation nor warranty, expressed or implied, is made as to the accuracy or completeness of the information contained in this document, and nothing contained herein is, or shall be relied upon, as a promise or representation, whether as to the past or the future. You are cautioned not to place undue reliance on these forward-looking statements.

This press release is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company's stock. This press release is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice. Except for ongoing obligations of the Company to disclose material information under the federal securities laws, the Company does not undertake any obligation to release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

Christensen Advisory

Christian Arnell

Phone: + 852 9040 0621

Email: <u>christian.arnell@christensencomms.com</u>